XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery

• Overall physician-determined XIENCE V® EECSS acute performance and deliverability. [ Time Frame: acute ] [ Designated as safety issue: No ]
• Physician-determined procedure success [ Time Frame: acute ] [ Designated as safety issue: No ]

• Total procedural costs based on resource utilization of disposable cath lab resources based on representative unit costs at the time of completion of the study. [ Time Frame: acute ] [ Designated as safety issue: No ]
• Physician-determined procedure success [ Time Frame: acute ] [ Designated as safety issue: No ]

• Individual component of adjunctive devices and drugs used during procedure. Number and type of guide wires [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure. Number and type of guiding catheters [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure. Number and type of balloon dilation catheters [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: Balloon pressures (pre-dilation/post-dilation pressures) [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: Number of stents [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: Amount of radiographic contrast [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: Fluoroscopy time [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: Duration of PCI procedure [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: IVUS use [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: Thienopyridine loading dose (prior to, during or after procedure) [ Time Frame: acute ] [ Designated as safety issue: No ]
• Individual component of adjunctive devices and drugs used during procedure: Aspirin loading dose (prior to, during or after procedure) [ Time Frame: acute ] [ Designated as safety issue: No ]
• Device Success [ Time Frame: acute ] [ Designated as safety issue: No ]

• Individual component comparisons of adjunctive devices and drugs used during procedure. [ Time Frame: acute ] [ Designated as safety issue: No ]
• Angiographic core lab qualitative and quantitative vessel and lesion measurements on all procedures, including core lab determination of procedure success. [ Time Frame: 14, 30, 180 days and 1, 2, 3, 4, and 5 years ] [ Designated as safety issue: No ]

This trial is to assess physician-determined XIENCE V® EECSS acute performance, deliverability and resource utilization in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience

This study will evaluate overall physician-determined XIENCE V® Everolimus Eluting Coronary Stent system (XIENCE V®) acute performance, deliverability and resource utilization in the catheterization lab in the "real world" as used by a broad group of physicians at a variety of health care facilities. This study will include all consecutively enrolled patients in the United States of America (USA) who consent to participate and receive XIENCE V® stents.

All patients undergoing planned or possible PCI should be invited to participate in the study.

• Atherosclerosis
• Coronary Artery Disease

General Inclusion Criteria:

• The patient agrees to participate in this study by signing the IRB approved informed consent form prior to the index procedure.
• Alternatively, the patient's legally authorized representative agrees to the patient's participation in this study and signs the informed consent form prior to the index procedure.

General Exclusion Criteria:

• Inability to obtain an informed consent is an exclusion criterion.